BDX Becton, Dickinson and Company Common Stock
NYSE · Health Care · Wyświetl na SEC EDGAR ↗ zamknij Paź 2, 2026 10-K/10-Q Sie 6, 2026BDX Migawka akcji Cena, kapitalizacja rynkowa, P/E, EPS, ROE, zadłużenie/kapitał własny, zakres 52-tygodniowy
BDX Wykres ceny akcji Dzienny OHLCV ze wskaźnikami technicznymi — przesuwaj, powiększaj i dostosowuj widok
Granularność słupków dostosowuje się do wybranego okresu — najedź kursorem na wykres, aby zobaczyć otwarcia/maksima/minima/zamknięcia dla danego słupka.
| Data ex-dywidendy | Podział | Typ |
|---|---|---|
| 10 lutego 2026 | 159-for-125 | Naprzód |
| 1 kwietnia 2022 | 41-for-40 | Naprzód |
| 21 sierpnia 1998 | 2-for-1 | Naprzód |
| 16 sierpnia 1996 | 2-for-1 | Naprzód |
| 1 marca 1993 | 2-for-1 | Naprzód |
| 3 marca 1986 | 2-for-1 | Naprzód |
O Becton, Dickinson and Company Common Stock Przegląd firmy z Wikipedii
Becton, Dickinson and Company (BD; also Becton Dickinson or Becton) is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain areas.
BD is ranked #211 in the 2024 Fortune 500 list based on its revenues for the fiscal year ending September 30, 2023.
History
The company was founded in 1897 in New York City by Maxwell Becton and Fairleigh S. Dickinson. It later moved its headquarters to New Jersey.
In 2004, BD agreed to pay out US$100 million to settle allegations from competitor Retractable Technologies that it had engaged in anti-competitive behavior to prevent the distribution of Retractable's syringes, which are designed to prevent needlestick injury. The lawsuit touched off a series of legal conflicts between the companies. Retractable would accuse BD of patent infringement after BD released a retractable needle of its own. Later Retractable would claim BD was falsely advertising its own brand of retractable needle as the “world’s sharpest needle”.
In October 2014, the company agreed to acquire CareFusion for a price of US$12.2 billion in cash and stock.
In April 2017, Becton, Dickinson and Company announced it would acquire C. R. Bard. The transaction was completed later that year, and the company became a wholly-owned subsidiary of BD, rebranded as Bard.
In May 2021, BD announced that it would spin off its diabetes care business (https://investors.bd.com/news-events/press-releases/detail/85/bd-announces-completion-of-embecta-corp-spinoff). The spinoff was completed on April 1, 2022, to form Embecta Corporation. Embecta Corporation is a standalone public company focused on diabetes care. The name "embecta" represents the company's commitment to people living with diabetes and its corporate heritage, with the "em-" prefix evoking empathy for people living with diabetes and the empowerment of the new company and the "bect" imbibed from Becton. Becton, Dickinson and Company entered into an agreement with Embecta Corporation to be their sole supplier of cannulas through 2032. This agreement protects patents and intellectual properties of both companies ensuring the quality and integrity of Embecta Corporation's cannulas used in their products.
In July 2021, BD announced it would acquire surgical scaffold maker Tepha, after having acquired Velano Vascular earlier the same month.
In 2024, BD announced it would acquire Edwards Lifesciences' critical care unit for $4.2 billion.
Finances
For the fiscal year 2017, Becton Dickinson reported earnings of US$1.030 billion, with an annual revenue of US$12.093 billion, an increase of 10.5% over the previous fiscal cycle. Becton Dickinson's shares traded at over US$192 per share, and its market capitalization was valued at over US$63 billion in November 2018.
Business segments
Currently there are three business segments.
BD Medical
In certain places, BD Medical also offers consulting and analytics related services. BD Medical's Consulting services are primarily targeted at hospitals, healthcare systems and networks of healthcare providers.
BD Life Sciences
Business units include Biosciences and Integrated Diagnostic Solutions.
Offerings include preanalytical solutions for sample management; immunology research, including flow cytometry and multiomics tools; microbiology and molecular diagnostics; lab automation and informatics; and differentiated reagents and assays.
In February 2026, BD Life Sciences was spun out and combined with the businesses of Waters Corporation.
BD Interventional
The company's line of plastic conical screwtop test tubes, known as 'Falcon tubes', is popular and the term is sometimes used as a generic term for such tubes.
Environmental and social track record
As of February 2010, BD was ranked 18th in the EPA Fortune 500 List of Green Power Purchasers. BD was also listed among the top 100 companies in Newsweek's 2009 Green Rankings ranking of the 500 largest American corporations based on environmental performance, policies, and reputation. BD placed third in the health care sector and 83rd overall. In addition, BD has been a component of the Dow Jones Sustainability World Index and the Dow Jones Sustainability North America Index for the four and five consecutive years, respectively.
Pfitzer et al. (2013) identify BD's development of a needleless injection system as an example of leading businesses' role in creating shared value.
Health and safety issues
In April 2016, the Occupational Safety and Health Administration fined BD US$112,700 for safety violations. They found repeat and serious violations of health and safety law that had resulted in two employees having partial finger amputations.
In 2020, C.R. Bard, Inc. and its parent company BD were fined $60 million USD for failing to adequately inform patients about health risks related to their transvaginal mesh devices.
Recalls
2007 Discardit II incident in Poland
In mid-2007, the firm's Discardit II series of syringes numbered 0607186 was withdrawn from hospitals and other medical services around Poland, about half a year after the discovery of remains of dark dust in some syringes, which were alleged to have been from this series. The newspaper Dziennik Online claimed that other series such as 06022444, 0603266, and 0607297 were also suspected of being contaminated. BD recalled and tested the syringes in question, and revealed sterile particulates in 0.013 percent of the products.
2010 Q-Syte Luer and IV Catheter partial recall
In February 2010 BD announced a voluntary product recall of certain lots of BD Q-Syte Luer Access Devices and BD Nexiva Closed IV Catheter Systems. BD stated that the use of the affected devices may cause an air embolism or leakage of blood and/or therapy, which may result in serious injury or death. The approximately 2.8 million BD Q-Syte and 2.9 million BD Nexiva units containing 5 million BD Q-Syte devices that were recalled were distributed in the United States, Asia, Canada, Europe, Mexico, the Middle East, South Africa, and South America. The recall was initiated on Oct. 28, 2009 after BD received complaints of problems due to air entry through a part of the device. BD stated that the cause of the problem was manufacturing deviation and claimed that it corrected the problem. BD announced that it notified customers about the recall by letter and has been working with the U.S. Food and Drug Administration and worldwide health agencies to coordinate recall activities.
2021 IV Giving Sets
In March 2021 BD announced a recall of infusion sets for CC, GP, VP, GW/GW800, SE, and IVAC 590 Alaris Pumps and gravity infusion sets and connectors following the news that a supplier falsified sterilisation documents going back ten years.
Lawsuits
In October 2024, BD agreed to settle around 38,000 US lawsuits brought by plaintiffs who claimed they were injured by BD's hernia meshes.
In December 2025, BD was sued by Tela Bio Inc., makers of a ovine forestomach matrix hernia mesh, who alleged that BD engaged in anticompetitive practices to push Tela out of the market for surgical meshes while raising prices for providers and patients.
Viral Orlando delivery driver incident
On September 6, 2026, in Orlando, Florida, a man identified on social media as Eric Smith, reportedly an employee of medical technology company Becton, Dickinson and Company (BD), drew widespread criticism after a confrontation with a food-delivery worker was captured on video and circulated online.
The video gained significant attention after being shared by social-media commentator Tizzyent on Instagram. During the encounter, the man was recorded making racist remarks toward the delivery worker, demanding her name. The footage subsequently went viral, generating calls on social media for BD to investigate the incident and address the alleged conduct of its employee.
Social-media users subsequently identified the man as Eric Smith and linked him to BD.
Incident recap
The incident reportedly occurred around 8:30 p.m. in Orlando, Florida, while a female delivery driver was making a food delivery. According to the driver, a man confronted her for allegedly blocking the road during her delivery, before questioning her immigration status, making remarks about "illegal immigrants," threatening to call ICE, and saying he would follow her.
The driver said she initially apologized and did not provoke the confrontation. Video of the encounter was later shared by Tizzyent on Instagram, where it went viral and drew widespread criticism.
Źródło: Wikipedia (Angielski), CC BY-SA 4.0 · Zobacz w Wikipedii ↗
Wyniki 10-letnie Trendy przychodów, zysku netto, marż i EPS
Wycena Wskaźniki P/E, P/S, P/B, EV/EBITDA — czy akcje są drogie, czy tanie?
| Wskaźnik | Trend 5-letni | BDX | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| P/E (TTM) | 53.4średnia z 5 lat ≈31.2 | ≈31.2 | · | · | |
| PEG Ratio (Współczynnik PEG) | ≈3.2 | · | · | · |
Mediana porównawcza jest obliczana na znormalizowanej podstawie dla każdej metryki i może nie zawsze odpowiadać podstawie TTM/MRQ pokazanej dla tej akcji.
Rentowność Marże brutto, operacyjne i netto; ROE, ROA, ROIC
| Wskaźnik | Trend 5-letni | BDX | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Marża Operacyjna (TTM) | 9.6%średnia z 5 lat ≈12.1% | ≈12.1% | · | · | |
| Marża EBITDA (TTM) | 21.0%średnia z 5 lat ≈23.6% | ≈23.6% | · | · | |
| Marża przed opodatkowaniem (TTM) | 7.2%średnia z 5 lat ≈9.5% | ≈9.5% | · | · | |
| Marża Zysku Netto (TTM) | 4.5%średnia z 5 lat ≈8.7% | ≈8.7% | · | · | |
| ROA (TTM) | 1.8%średnia z 5 lat ≈3.2% | ≈3.2% | · | · | |
| ROE (TTM) | 3.8%średnia z 5 lat ≈7.0% | ≈7.0% | · | · | |
| ROIC | 5.3%średnia z 5 lat ≈5.3% | ≈5.3% | · | · |
Zdrowie finansowe Dług, płynność, wypłacalność — siła bilansu
| Wskaźnik | Trend 5-letni | BDX | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Dług / Kapitał Własny (MRQ) | 0.6średnia z 5 lat ≈0.6 | ≈0.6 | · | · | |
| Wskaźnik bieżący (MRQ) | 0.9średnia z 5 lat ≈1.2 | ≈1.2 | · | · | |
| Quick Ratio (Wskaźnik Szybkości) | 0.4średnia z 5 lat ≈0.5 | ≈0.5 | · | · | |
| Dług długoterminowy / Kapitał własny (MRQ) | 0.6średnia z 5 lat ≈0.6 | ≈0.6 | · | · | |
| Interest Coverage (Pokrycie odsetek) | 4.2średnia z 5 lat ≈5.0 | ≈5.0 | · | · |
Rozwój Wzrost przychodów, EPS i zysku netto: r/r, CAGR 3-letni, CAGR 5-letni
| Wskaźnik | Trend 5-letni | BDX | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Revenue YoY (Przychody R/R) | 8.2%średnia z 5 lat ≈6.5% | ≈6.5% | · | · | |
| Revenue CAGR 3Y (Przychody CAGR 3L) | 5.0%średnia z 5 lat ≈4.4% | ≈4.4% | · | · | |
| Revenue CAGR 5Y (Przychody CAGR 5L) | 6.3% | · | · | · | |
| EPS YoY | -0.68%średnia z 5 lat ≈28.1% | ≈28.1% | · | · | |
| Net Income YoY (Zysk Netto R/R) | -1.6%średnia z 5 lat ≈24.2% | ≈24.2% | · | · | |
| EPS CAGR 3Y (CAGR z EPS 3 lata) | -0.34%średnia z 5 lat ≈5.6% | ≈5.6% | · | · | |
| EPS CAGR 5Y (CAGR z EPS 5 lat) | 16.5% | · | · | · | |
| Net Income CAGR 3Y (CAGR z zysku netto 3 lata) | -1.9%średnia z 5 lat ≈3.6% | ≈3.6% | · | · | |
| Net Income CAGR 5Y (CAGR z zysku netto 5 lat) | 13.9% | · | · | · |
Efektywność kapitałowa Rotacja aktywów, rotacja zapasów, rotacja należności
| Wskaźnik | Trend 5-letni | BDX | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Asset Turnover (Rotacja aktywów) | 0.4średnia z 5 lat ≈0.4 | ≈0.4 | · | · | |
| Inventory Turnover (Rotacja zapasów) | 3.1średnia z 5 lat ≈3.4 | ≈3.4 | · | · | |
| Receivables Turnover (Rotacja należności) | 7.2średnia z 5 lat ≈7.9 | ≈7.9 | · | · | |
| Revenue / Employee (Przychody / pracownika) | ≈$303.3K | · | · | · |
wartość · ≈ średnia z 5 lat · mediana branżowa · werdykt względem mediany
Dywidendy Stopa dywidendy, wskaźnik wypłaty, historia dywidend, 5-letni CAGR
| Data ex-dywidendy | Kwota | Waluta | Stopa zwrotu |
|---|---|---|---|
| Wrz 9, 2026 | $1,05 | USD | ≈2.2% |
| Cze 9, 2026 | $1,05 | USD | ≈2.5% |
| Mar 10, 2026 | $1,05 | USD | ≈2.1% |
| Gru 8, 2025 | $0,83 | USD | ≈2.2% |
| Wrz 8, 2025 | $0,82 | USD | ≈2.2% |
| Cze 9, 2025 | $0,82 | USD | ≈2.4% |
| Mar 10, 2025 | $0,82 | USD | ≈1.7% |
| Gru 9, 2024 | $0,82 | USD | ≈1.7% |
| Wrz 9, 2024 | $0,75 | USD | ≈1.6% |
| Cze 10, 2024 | $0,75 | USD | ≈1.6% |
| Mar 7, 2024 | $0,75 | USD | ≈1.6% |
| Gru 7, 2023 | $0,75 | USD | ≈1.6% |
| Wrz 7, 2023 | $0,72 | USD | ≈1.4% |
| Cze 8, 2023 | $0,72 | USD | ≈1.4% |
| Mar 9, 2023 | $0,72 | USD | ≈1.5% |
| Gru 8, 2022 | $0,72 | USD | ≈1.4% |
| Wrz 8, 2022 | $0,68 | USD | ≈1.3% |
| Cze 8, 2022 | $0,68 | USD | ≈1.3% |
| Mar 9, 2022 | $0,67 | USD | ≈1.3% |
| Gru 9, 2021 | $0,67 | USD | ≈1.4% |
Historia zysków EPS faktyczny vs szacowany, zaskoczenie %, wskaźnik trafień, data następnych wyników
| Okres | Raport | EPS Actual | EPS Szacowany | Niespodzianka |
|---|---|---|---|---|
| 30 czerwca 2026 | $3.23 | $3.17 | 1.8% | |
| 31 marca 2026 | $2.90 | $2.80 | 3.5% | |
| 31 grudnia 2025 | $2.91 | $2.84 | 2.4% | |
| 30 września 2025 | $3.96 | $3.96 | -0.05% | |
| 30 czerwca 2025 | $3.68 | $3.44 | 7.1% | |
| 31 marca 2025 | $3.35 | $3.31 | 1.1% |
Pełne podstawowe wskaźniki Wszystkie wskaźniki roczne — rachunek zysków i strat, bilans, przepływy pieniężne
Rachunek zysków i strat
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $21.84B | $20.18B | $19.37B | $18.87B | $19.13B | $16.07B | $17.29B | $15.98B | $12.09B | $12.48B | $10.28B | $8.45B | |
| Cost of Revenue | $11.91B | $11.05B | $11.20B | $10.39B | $10.50B | $9.28B | $9.00B | $8.71B | $6.13B | $6.49B | $5.59B | $4.14B | |
| Gross Profit | · | · | · | · | · | $7.58B | $8.29B | $7.27B | $5.94B | $5.99B | $4.70B | $4.30B | |
| R&D Expense | $1.26B | $1.19B | $1.24B | $1.26B | $1.28B | $1.04B | $1.06B | $1.00B | $770M | $828M | $632M | $550M | |
| SG&A Expense | $5.28B | $4.86B | $4.72B | $4.71B | $4.72B | $4.18B | $4.33B | $4.02B | $2.91B | $3.00B | $2.56B | $2.15B | |
| Operating Expenses | $19.26B | $17.78B | $17.26B | $16.59B | $16.88B | $15.16B | $15.53B | $14.47B | $10.57B | $11.05B | $9.21B | $6.84B | |
| Operating Income | $2.58B | $2.40B | $2.11B | $2.28B | $2.25B | $912M | $1.76B | $1.51B | $1.52B | $1.43B | $1.07B | $1.61B | |
| Interest Expense | $613M | $528M | $452M | $398M | $469M | $528M | $639M | $706M | $521M | $388M | $371M | $135M | |
| Interest Income | $38M | $163M | $49M | $16M | $9M | $7M | $12M | $65M | $76M | $21M | $15M | $46M | |
| Other Non-op | $-123M | $-28M | $-46M | $-117M | $-99M | $23M | $43M | $305M | $-101M | $11M | $21M | $5M | |
| Pretax Income | $1.88B | $2.00B | $1.66B | $1.78B | $1.69B | $414M | $1.18B | $1.17B | $976M | $1.07B | $739M | $1.52B | |
| Income Tax | $203M | $300M | $132M | $148M | $88M | $62M | $-57M | $862M | $-124M | $97M | $44M | $337M | |
| Net Income | $1.68B | $1.71B | $1.48B | $1.78B | $2.09B | $874M | $1.23B | $311M | $1.10B | $976M | $695M | $1.19B | |
| EPS (Basic) | $5.83 | $5.88 | $4.97 | $5.93 | $6.92 | $2.75 | $4.01 | $0.62 | $4.70 | $4.59 | $3.43 | $6.13 | |
| EPS (Diluted) | $5.82 | $5.86 | $4.94 | $5.88 | $6.85 | $2.71 | $3.94 | $0.60 | $4.60 | $4.49 | $3.35 | $5.99 | |
| Shares (Basic) | 287,648,000 | 289,763,000 | 286,282,000 | 285,005,000 | 289,288,000 | 278,971,000 | 269,943,000 | 258,354,000 | 218,943,000 | 212,702,000 | 202,537,000 | 193,299,000 | |
| Shares (Diluted) | 288,509,000 | 291,009,000 | 288,392,000 | 287,364,000 | 292,089,000 | 282,402,000 | 274,775,000 | 264,621,000 | 223,588,000 | 217,536,000 | 207,509,000 | 197,709,000 | |
| EBITDA | $5.04B | $4.68B | $4.40B | $4.51B | $5.07B | $3.64B | $4.01B | $3.48B | $2.57B | $2.54B | $1.97B | $2.17B |
Bilans
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $567M | $1.72B | $1.42B | $1.01B | $2.28B | $2.83B | $536M | $1.14B | $14.18B | $1.54B | $1.42B | $1.86B | |
| Receivables | $2.40B | $3.03B | $2.53B | $2.19B | $2.35B | $2.40B | $2.35B | $2.32B | $1.74B | $1.62B | $1.62B | $1.19B | |
| Inventory | $3.15B | $3.84B | $3.27B | $3.22B | $2.74B | $2.74B | $2.58B | $2.45B | $1.82B | $1.72B | $1.96B | $1.50B | |
| Other Current Assets | $1.38B | $1.29B | $1.38B | $1.56B | $1.05B | $891M | $1.12B | $1.25B | $871M | $480M | $563M | $698M | |
| Current Assets | $9.26B | $10.47B | $8.68B | $8.14B | $8.84B | $8.97B | $6.66B | $7.41B | $18.63B | $6.37B | $5.66B | $6.13B | |
| PP&E (Net) | $6.38B | $6.82B | $6.56B | $6.01B | $6.00B | $5.92B | $5.66B | $5.38B | $4.64B | $3.90B | $4.06B | $3.60B | |
| PP&E (Gross) | $13.66B | $14.38B | $13.58B | $12.41B | $12.09B | $11.92B | $11.13B | $10.48B | $9.39B | $8.42B | $8.28B | $7.76B | |
| Accum. Depreciation | $7.27B | $7.56B | $7.02B | $6.40B | $6.09B | $6.00B | $5.47B | $5.11B | $4.75B | $4.52B | $4.22B | $4.16B | |
| Goodwill | $25.96B | $26.46B | $24.52B | $24.62B | $23.89B | $23.60B | $23.38B | $23.60B | $7.56B | $7.42B | $7.54B | $1.09B | |
| Intangibles | $9.23B | $10.87B | $10.90B | $12.26B | $12.73B | $13.77B | · | · | · | · | · | · | |
| Other Non-current Assets | $2.38B | $2.62B | $2.08B | $1.85B | $1.95B | $1.69B | $1.09B | $1.08B | $1.01B | $824M | $717M | $488M | |
| Total Assets | $55.33B | $57.29B | $52.78B | $52.93B | $53.87B | $54.01B | $51.77B | $53.90B | $37.73B | $25.59B | $26.48B | $12.38B | |
| Accounts Payable | $6.11B | $1.90B | $1.64B | $1.70B | $1.74B | $1.35B | $1.09B | $1.11B | $797M | $665M | $631M | $401M | |
| Accrued Liabilities | $3.10B | $3.48B | $2.60B | $2.60B | $2.87B | $2.64B | $2.13B | $2.25B | $1.39B | $1.57B | $1.62B | $1.05B | |
| Current Liabilities | $8.31B | $8.96B | $6.64B | $7.81B | $6.63B | $5.84B | $5.66B | $7.22B | $3.34B | $4.40B | $4.38B | $2.23B | |
| Capital Leases | $704M | $667M | $414M | $384M | $344M | $336M | · | · | · | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | · | $1.95B | $130M | |
| Other Non-current Liabilities | $2.63B | $3.56B | $4.58B | $5.05B | $5.21B | $5.75B | $5.68B | $5.74B | $1.61B | $1.68B | $2.43B | $383M | |
| Long-term Debt | · | · | · | · | · | · | · | · | · | · | $12.12B | $3.77B | |
| Total Debt | $17.62B | $17.94B | $14.74B | $13.89B | $17.11B | $17.22B | $18.08B | $18.89B | $18.67B | $10.55B | $12.12B | $3.77B | |
| Common Stock | $371M | $371M | $371M | $365M | $365M | $365M | $347M | $347M | $347M | $333M | $333M | $333M | |
| Retained Earnings | $16.62B | $16.14B | $15.54B | $15.16B | $13.83B | $12.79B | $12.91B | $12.60B | $13.11B | $12.73B | $12.31B | $12.11B | |
| Treasury Stock | $9.81B | $8.81B | $8.30B | $8.33B | $7.72B | $6.14B | $6.19B | $6.24B | $8.43B | $8.21B | $8.24B | $8.60B | |
| AOCI | $-1.90B | $-1.73B | $-1.55B | $-1.49B | $-2.09B | $-2.55B | $-2.28B | $-1.91B | $-1.72B | $-1.93B | $-1.74B | $-1.00B | |
| Stockholders' Equity | $25.39B | $25.89B | $25.80B | $25.28B | $23.68B | $23.77B | $21.08B | $20.99B | $12.95B | $7.63B | $7.16B | $5.05B | |
| Liabilities + Equity | $55.33B | $57.29B | $52.78B | $52.93B | $53.87B | $54.01B | $51.77B | $53.90B | $37.73B | $25.59B | $26.48B | $12.45B |
Przepływy pieniężne
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $2.46B | $2.29B | $2.29B | $2.23B | $2.23B | $2.12B | $2.25B | $1.98B | $1.09B | $1.11B | $891M | $562M | |
| Stock-based Comp | $258M | $247M | $259M | $233M | $229M | $236M | $261M | $322M | $174M | $196M | $166M | $113M | |
| Deferred Tax | $-474M | $-211M | $-622M | $-129M | $-280M | $-285M | $-633M | $-262M | $-74M | $-519M | $-274M | $-94M | |
| Amort. of Intangibles | $1.59B | $1.47B | $1.47B | $1.43B | $1.40B | $1.38B | $1.50B | $1.25B | $553M | $552M | $346M | $84M | |
| Restructuring | $275M | $387M | $239M | $123M | $44M | $84M | · | · | $85M | $526M | $271M | · | |
| Other Non-cash | $-494M | $-183M | $-419M | $-1.64B | $333M | $553M | $216M | $516M | $262M | $792M | $252M | $-20M | |
| Operating Cash Flow | $3.43B | $3.84B | $2.99B | $2.47B | $4.13B | $2.94B | $3.33B | $2.87B | $2.55B | $2.56B | $1.73B | $1.75B | |
| CapEx | $760M | $725M | $874M | $973M | $1.19B | $769M | $957M | $895M | $727M | $693M | $596M | $592M | |
| Investing Cash Flow | $-818M | $-5.51B | $-716M | · | $-1.88B | $-1.23B | $-741M | $-15.73B | $-883M | $-669M | $-8.32B | $-948M | |
| Debt Issued | $0 | $4.52B | $1.66B | $497M | $4.87B | $3.39B | $2.22B | $5.09B | $11.46B | $0 | $6.16B | $0 | |
| Net Debt Issued | $-1.79B | $3.38B | $-493M | $-308M | $-243M | $-1.27B | $-2.52B | $1.09B | $7.48B | $-752M | $6.16B | · | |
| Stock Repurchased | $1.00B | $500M | $0 | $500M | $1.75B | $0 | $0 | $0 | $220M | $0 | $0 | $400M | |
| Net Stock Activity | $-1.00B | $-500M | $0 | $-500M | $-1.75B | · | $0 | $0 | $-220M | $0 | $0 | $-400M | |
| Dividends Paid | $1.20B | $1.10B | $1.11B | $1.08B | $1.05B | $1.03B | $984M | $927M | $677M | $562M | $485M | $421M | |
| Financing Cash Flow | $-3.62B | $2.09B | $-1.96B | · | $-3.31B | $22M | $-3.22B | $-58M | $10.98B | $-1.76B | $6.19B | $-807M | |
| Net Change in Cash | $-1.00B | $375M | $322M | $-1.23B | $-525M | $2.33B | $-646M | $-12.94B | $12.64B | $117M | $-436M | $-29M | |
| Taxes Paid | $599M | $653M | $629M | $532M | $671M | $523M | $536M | $235M | $265M | $218M | $240M | $330M | |
| Free Cash Flow | $2.67B | $3.12B | $2.12B | $1.50B | $3.42B | $2.73B | $2.37B | $1.97B | $1.82B | $1.87B | $1.13B | $1.15B | |
| Levered FCF | $2.12B | $2.67B | $1.70B | $1.13B | $2.98B | $2.26B | $1.70B | $1.78B | $1.24B | $1.51B | $785M | $1.05B |
Rentowność
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | · | · | · | · | · | 44.3% | 47.9% | 45.4% | 49.1% | 48.0% | 45.7% | · | |
| Operating Margin | 11.8% | 11.9% | 10.9% | 12.1% | 13.8% | 8.7% | 10.2% | 9.4% | 12.2% | 11.5% | 10.4% | 19.0% | |
| Net Margin | 7.7% | 8.5% | 7.7% | 9.4% | 10.3% | 5.1% | 7.1% | 1.9% | 9.1% | 7.8% | 6.8% | 14.0% | |
| Pretax Margin | 8.6% | 9.9% | 8.6% | 9.4% | 11.1% | 5.8% | 6.8% | 7.3% | 8.1% | 8.6% | 7.2% | 18.0% | |
| EBITDA Margin | 23.1% | 23.2% | 22.7% | 23.9% | 25.1% | 21.2% | 23.2% | 21.7% | 21.2% | 20.4% | 19.1% | 25.7% | |
| ROA | 3.0% | 3.1% | 2.8% | 3.3% | 3.9% | 1.7% | 2.3% | 0.68% | 3.5% | 3.8% | 3.5% | 9.6% | |
| ROE | 6.5% | 6.6% | 5.8% | 7.3% | 8.8% | 3.9% | 5.9% | 1.8% | 10.7% | 13.2% | 11.4% | 23.5% | |
| ROIC | 5.3% | 4.7% | 4.8% | 5.3% | 6.4% | 3.2% | 4.7% | 1.0% | 5.3% | 7.1% | 5.2% | 14.2% |
Płynność i wypłacalność
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.1 | 1.2 | 1.3 | 1.0 | 1.3 | 1.5 | 1.2 | 1.0 | 5.6 | 1.4 | 1.4 | 2.7 | |
| Quick Ratio | 0.4 | 0.5 | 0.6 | 0.4 | 0.7 | 0.9 | 0.5 | 0.5 | 4.8 | 0.7 | 0.7 | 1.4 | |
| Debt / Equity | 0.7 | 0.7 | 0.6 | 0.5 | 0.7 | 0.7 | 0.9 | 0.9 | 1.4 | 1.4 | 1.7 | 0.7 | |
| LT Debt / Equity | 0.7 | 0.7 | 0.6 | 0.5 | 0.7 | 0.7 | 0.9 | 0.9 | 1.4 | 1.4 | 1.6 | 0.7 | |
| Interest Coverage | 4.2 | 4.5 | 4.7 | 5.7 | 6.0 | 2.8 | 2.8 | 2.1 | 2.8 | 3.7 | 2.9 | 11.9 |
Efektywność
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.3 | 0.3 | 0.3 | 0.4 | 0.5 | 0.5 | 0.7 | |
| Inventory Turnover | 3.1 | 3.1 | 3.4 | 3.5 | 3.9 | 3.6 | 3.6 | 4.1 | 3.5 | 3.5 | 3.2 | 2.9 | |
| Receivables Turnover | 7.2 | 7.2 | 8.2 | 8.3 | 8.3 | 7.2 | 7.4 | 7.9 | 7.2 | 7.7 | 7.3 | 7.0 |
Na akcję
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue / Share | $75.70 | $69.34 | $67.17 | $65.67 | $69.32 | $60.61 | $62.92 | $60.40 | $54.09 | $57.38 | $49.55 | $42.72 | |
| Cash Flow / Share | $11.89 | $13.21 | $10.37 | $8.60 | $15.91 | $12.53 | $12.12 | $10.83 | $11.40 | $11.76 | $8.34 | $8.83 | |
| Dividend Paid / Share | $4.16 | $3.80 | $3.64 | $3.48 | $3.32 | $3.16 | $3.08 | $3.00 | $2.92 | $2.64 | $2.40 | $2.18 | |
| EPS (TTM) | $5.82 | $5.86 | $4.94 | $5.88 | $6.85 | $2.71 | $3.94 | $0.60 | $4.60 | $4.49 | $3.35 | $5.99 |
Stopy Wzrostu
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 8.2% | 4.2% | 2.7% | -1.4% | 19.0% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 5.0% | 1.8% | 6.4% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 6.3% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | -0.68% | 18.6% | -16.0% | -14.2% | 152.8% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | -0.34% | -5.1% | 22.2% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | 16.5% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | -1.6% | 14.9% | -16.6% | -15.0% | 139.4% | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | -1.9% | -6.6% | 19.3% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | 13.9% | · | · | · | · | · | · | · | · | · | · | · | |
| Dividends Paid CAGR 5Y | 3.1% | · | · | · | · | · | · | · | · | · | · | · |
Wycena (TTM)
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $21.84B | $20.18B | $19.37B | $18.87B | $19.13B | $16.07B | $17.29B | $15.98B | $12.09B | $12.48B | $10.28B | $8.45B | |
| Net Income TTM | $1.68B | $1.71B | $1.48B | $1.78B | $2.09B | $874M | $1.23B | $311M | $1.10B | $976M | $695M | $1.19B | |
| P/E | 25.3 | 32.3 | 41.1 | 29.8 | 27.5 | 65.9 | 49.2 | 333.6 | 32.7 | 30.7 | 30.4 | 14.6 | |
| Earnings Yield | 4.0% | 3.1% | 2.4% | 3.4% | 3.6% | 1.5% | 2.0% | 0.30% | 3.1% | 3.3% | 3.3% | 6.9% | |
| Payout Ratio | 71.3% | 64.5% | 75.1% | 60.8% | 50.1% | 117.4% | 79.8% | 298.1% | 61.6% | 57.6% | 69.8% | 35.5% | |
| Annual Payout | $1.20B | $1.10B | $1.11B | $1.08B | $1.05B | $1.03B | $984M | $927M | $677M | $562M | $485M | $421M |
Rachunek zysków i strat
| Wskaźnik | Trend | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.98B | $4.71B | $5.25B | $5.89B | $4.73B | $4.48B | $5.17B | $5.44B | $4.99B | $5.04B | $4.71B | $5.09B | $4.88B | $4.82B | $4.59B | $4.76B | |
| Cost of Revenue | $2.67B | $2.56B | $2.84B | $3.09B | $2.49B | $2.62B | $2.93B | $2.95B | $2.68B | $2.74B | $2.68B | $3.38B | $2.78B | $2.59B | $2.45B | $2.68B | |
| R&D Expense | $258M | $249M | $306M | $323M | $230M | $232M | $343M | $302M | $299M | $299M | $290M | $281M | $306M | $337M | $313M | $300M | |
| SG&A Expense | $1.26B | $1.21B | $1.39B | $1.37B | $1.16B | $1.12B | $1.32B | $1.25B | $1.20B | $1.19B | $1.21B | $1.14B | $1.19B | $1.21B | $1.19B | $1.18B | |
| Operating Expenses | $4.32B | $4.62B | $4.70B | $5.19B | $3.99B | $4.10B | $4.71B | $4.81B | $4.39B | $4.31B | $4.27B | $4.74B | $4.33B | $4.19B | $4.00B | $4.27B | |
| Operating Income | $663M | $93M | $552M | $698M | $739M | $383M | $453M | $622M | $602M | $734M | $439M | $349M | $549M | $628M | $585M | $489M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $125M | $111M | $113M | $119M | $118M | $102M | $104M | |
| Interest Income | $4M | $9M | $4M | $5M | $4M | $5M | $23M | $55M | $48M | $26M | $34M | $9M | $24M | $10M | $6M | $7M | |
| Other Non-op | $19M | $86M | $-10M | $-36M | $-22M | $-36M | $-16M | $-9M | $-13M | $-2M | $-4M | $-63M | $17M | $8M | $-8M | $-73M | |
| Pretax Income | $554M | $39M | $393M | $509M | $569M | $201M | $306M | $513M | $500M | $633M | $359M | $181M | $471M | $529M | $481M | $320M | |
| Income Tax | $102M | $76M | $11M | $16M | $118M | $43M | $3M | $114M | $13M | $96M | $77M | $28M | $64M | $68M | $-28M | $33M | |
| Net Income | $377M | $-311M | $382M | $493M | $574M | $308M | $303M | $400M | $487M | $537M | $281M | $108M | $407M | $460M | $509M | $288M | |
| EPS (Basic) | $1.37 | $-1.11 | $1.34 | $1.71 | $2.00 | $1.07 | $1.05 | $1.38 | $1.68 | $1.85 | $0.97 | $0.35 | $1.37 | $1.54 | $1.71 | $0.94 | |
| EPS (Diluted) | $1.37 | $-1.11 | $1.34 | $1.71 | $2.00 | $1.07 | $1.04 | $1.37 | $1.68 | $1.85 | $0.96 | $0.35 | $1.36 | $1.53 | $1.70 | $0.92 | |
| Shares (Basic) | 274,788,000 | 280,640,000 | 285,582,000 | · | 287,170,000 | 287,293,000 | 289,505,000 | · | 289,562,000 | 289,518,000 | 290,113,000 | · | 286,317,000 | 284,292,000 | 283,887,000 | · | |
| Shares (Diluted) | 275,158,000 | 280,640,000 | 285,845,000 | · | 287,223,000 | 287,737,000 | 290,389,000 | · | 290,253,000 | 290,344,000 | 291,398,000 | · | 287,944,000 | 285,645,000 | 285,340,000 | · | |
| EBITDA | $1.23B | $656M | $1.17B | · | $882M | $546M | $1.06B | · | $602M | $734M | $1.00B | · | $549M | $628M | $1.15B | · |
Bilans
| Wskaźnik | Trend | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $708M | $813M | $740M | $641M | $735M | $667M | $711M | $1.72B | $4.46B | $2.35B | $1.18B | · | $923M | $1.98B | $612M | · | |
| Receivables | $2.36B | $2.21B | $2.51B | $2.99B | $2.94B | $3.03B | $2.64B | $3.03B | $2.60B | $2.56B | $2.27B | · | $2.41B | $2.41B | $2.28B | · | |
| Inventory | $3.32B | $3.36B | $4.08B | $3.89B | $3.95B | $3.72B | $3.86B | $3.84B | $3.25B | $3.23B | $3.30B | · | $3.59B | $3.66B | $3.60B | · | |
| Other Current Assets | $1.59B | $1.43B | $1.56B | $1.51B | $1.28B | $1.15B | $1.33B | $1.29B | $1.02B | $1.33B | $1.35B | · | $1.28B | $1.44B | $1.54B | · | |
| Current Assets | $8.14B | $8.01B | $9.19B | $9.26B | $9.00B | $8.67B | $8.66B | $10.47B | $12.21B | $10.34B | $8.16B | · | $8.59B | $9.59B | $8.18B | · | |
| PP&E (Net) | $6.08B | $6.08B | $6.97B | $7.00B | $6.82B | $6.65B | $6.60B | $6.82B | $6.52B | $6.59B | $6.65B | · | $6.47B | $6.36B | $6.25B | · | |
| PP&E (Gross) | $13.60B | $13.55B | $15.24B | $15.11B | $14.85B | $14.41B | $14.16B | $14.38B | $13.92B | $13.93B | $13.90B | · | $13.47B | $13.20B | $12.93B | · | |
| Accum. Depreciation | $7.52B | $7.47B | $8.27B | $8.12B | $8.04B | $7.76B | $7.55B | $7.56B | $7.40B | $7.33B | $7.25B | · | $7.00B | $6.85B | $6.68B | · | |
| Goodwill | $25.94B | $25.95B | $26.62B | $26.61B | $26.60B | $26.44B | $26.33B | $26.46B | $24.55B | $24.57B | $24.60B | $24.52B | $24.58B | $24.78B | $24.76B | $24.62B | |
| Intangibles | $8.02B | $8.35B | $9.01B | $9.39B | $9.77B | $10.12B | $10.47B | $10.87B | $9.86B | $10.21B | $10.57B | · | $11.27B | $11.63B | $11.94B | · | |
| Other Non-current Assets | $2.55B | $2.43B | $3.04B | $3.06B | $2.70B | $2.58B | $2.59B | $2.62B | $2.40B | $2.40B | $2.26B | · | $2.06B | $1.99B | $1.96B | · | |
| Total Assets | $50.73B | $50.83B | $54.84B | $55.33B | $54.90B | $54.47B | $54.66B | $57.29B | $55.58B | $54.16B | $52.27B | · | $53.02B | $54.39B | $53.13B | · | |
| Accounts Payable | $6.11B | $5.93B | $6.14B | $1.97B | $6.35B | $6.09B | $6.35B | $1.90B | $5.41B | $5.31B | $5.52B | · | $5.02B | $5.09B | $5.44B | · | |
| Accrued Liabilities | · | · | · | $3.10B | · | · | · | $3.48B | · | · | · | · | · | · | · | · | |
| Current Liabilities | $9.40B | $8.51B | $8.76B | $8.31B | $8.16B | $7.69B | $7.66B | $8.96B | $6.61B | $7.33B | $7.54B | · | $6.88B | $7.30B | $7.62B | · | |
| Capital Leases | · | · | · | $704M | · | · | · | $667M | · | · | · | · | · | · | · | · | |
| Other Non-current Liabilities | $2.39B | $2.46B | $2.81B | $2.93B | $2.83B | $3.00B | $3.42B | $3.56B | $4.07B | $4.30B | $4.41B | · | $4.37B | $4.47B | $4.86B | · | |
| Total Debt | $13.51B | $14.71B | $16.92B | · | $17.53B | $17.67B | $17.44B | · | $18.13B | $15.99B | $14.09B | · | $14.93B | $16.01B | $14.27B | · | |
| Common Stock | $371M | $371M | $371M | $371M | $371M | $371M | $371M | $371M | $371M | $371M | $371M | · | $371M | $365M | $365M | · | |
| Retained Earnings | $17.51B | $17.39B | $16.70B | $16.62B | $16.43B | $16.15B | $16.14B | $16.14B | $16.02B | $15.80B | $15.54B | · | $15.69B | $15.56B | $15.38B | · | |
| Treasury Stock | $12.06B | $11.66B | $10.06B | $9.81B | $9.56B | $9.56B | $9.43B | $8.81B | $8.81B | $8.81B | $8.83B | · | $8.32B | $8.33B | $8.33B | · | |
| AOCI | $-1.65B | $-1.76B | $-1.86B | $-1.90B | $-1.81B | $-1.72B | $-1.68B | $-1.73B | $-1.58B | $-1.53B | $-1.51B | · | $-1.51B | $-1.57B | $-1.56B | $-1.49B | |
| Stockholders' Equity | $24.42B | $24.13B | $25.28B | $25.39B | $25.47B | $25.24B | $25.20B | $25.89B | $25.87B | $25.65B | $25.33B | · | $25.94B | $25.69B | $25.47B | · | |
| Liabilities + Equity | $50.73B | $50.83B | $54.84B | $55.33B | $54.90B | $54.47B | $54.66B | $57.29B | $55.58B | $54.16B | $52.27B | · | $53.02B | $54.39B | $53.13B | · |
Przepływy pieniężne
| Wskaźnik | Trend | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $564M | $563M | $614M | $629M | $575M | $567M | $607M | $586M | $568M | $571M | $561M | $587M | $571M | $563M | $567M | $581M | |
| Stock-based Comp | $55M | $58M | $91M | $55M | $54M | $59M | $90M | $51M | $53M | $60M | $83M | $58M | $56M | $56M | $89M | $49M | |
| Amort. of Intangibles | $365M | $380M | $397M | $398M | $388M | $387M | $395M | $375M | $362M | $366M | $365M | $367M | $367M | $366M | $365M | $366M | |
| Restructuring | $48M | $482M | $75M | $88M | $58M | $63M | $66M | $125M | $95M | $98M | $69M | $119M | $61M | $33M | $26M | $51M | |
| Other Non-cash | · | · | $-845M | · | · | · | $-677M | · | · | · | $82M | · | · | · | $-1.43B | · | |
| Operating Cash Flow | $776M | $671M | $657M | $1.35B | $1.22B | $164M | $693M | $1.18B | $1.30B | $514M | $855M | $1.32B | $1.08B | $185M | $399M | $973M | |
| CapEx | $143M | $125M | $108M | $352M | $174M | $129M | $105M | $296M | $179M | $134M | $116M | $294M | $191M | $181M | $208M | $315M | |
| Investing Cash Flow | · | · | $-183M | $-494M | $-336M | $-192M | $204M | $-3.94B | $-288M | $-1.06B | $-233M | $137M | $-329M | $-233M | $-291M | · | |
| Net Debt Issued | $-2.00B | $-2.00B | $0 | · | · | · | $-875M | · | · | · | $0 | · | · | · | $-528M | · | |
| Stock Repurchased | $0 | $2.00B | $250M | $250M | $0 | $0 | $750M | $0 | $0 | $0 | $500M | $0 | $0 | $0 | $0 | $500M | |
| Net Stock Activity | · | · | $-250M | · | · | · | $-750M | · | · | · | $-500M | · | · | · | · | · | |
| Dividends Paid | $286M | $290M | $299M | $297M | $299M | $298M | $302M | $275M | $275M | $275M | $275M | $265M | $286M | $282M | $281M | $270M | |
| Financing Cash Flow | · | · | $-302M | $-809M | $-841M | $-39M | $-1.93B | $124M | $1.12B | $1.71B | $-862M | $-997M | $-1.79B | $1.37B | $-534M | · | |
| Net Change in Cash | $-152M | $64M | $174M | $53M | $51M | $-66M | $-1.04B | $-2.63B | $2.09B | $1.16B | $-247M | $456M | $-1.04B | $1.32B | $-415M | $-1.60B | |
| Free Cash Flow | · | · | $549M | · | · | · | $588M | · | · | · | $739M | · | · | · | $191M | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | · | $652M | · | · | · | $83M | · |
Rentowność
| Wskaźnik | Trend | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 13.3% | 2.0% | 10.5% | · | 16.0% | 10.4% | 8.8% | · | 12.1% | 14.5% | 9.3% | · | 11.2% | 13.0% | 12.8% | · | |
| Net Margin | 7.6% | -6.6% | 7.3% | · | 10.4% | 5.8% | 5.9% | · | 9.8% | 10.6% | 6.0% | · | 8.3% | 9.5% | 11.1% | · | |
| Pretax Margin | 11.1% | 0.83% | 7.5% | · | 12.8% | 6.9% | 5.9% | · | 10.0% | 12.6% | 7.6% | · | 9.7% | 11.0% | 10.5% | · | |
| EBITDA Margin | 24.6% | 13.9% | 22.2% | · | 16.0% | 10.4% | 20.5% | · | 12.1% | 14.5% | 21.2% | · | 11.2% | 13.0% | 25.1% | · | |
| ROA | 0.71% | -0.59% | 0.70% | · | 1.0% | 0.57% | 0.57% | · | 0.90% | 0.99% | 0.53% | · | 0.77% | 0.84% | 0.96% | · | |
| ROE | 1.5% | -1.3% | 1.5% | · | 2.2% | 1.2% | 1.2% | · | 1.9% | 2.1% | 1.1% | · | 1.6% | 1.8% | 2.1% | · | |
| ROIC | 1.4% | -0.23% | 1.3% | · | 1.7% | 1.1% | 1.1% | · | 1.3% | 1.5% | 0.87% | · | 1.2% | 1.3% | 1.6% | · |
Płynność i wypłacalność
| Wskaźnik | Trend | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.9 | 0.9 | 1.0 | · | 1.1 | 1.1 | 1.1 | · | 1.8 | 1.4 | 1.1 | · | 1.2 | 1.3 | 1.1 | · | |
| Quick Ratio | 0.3 | 0.4 | 0.4 | · | 0.5 | 0.5 | 0.4 | · | 1.1 | 0.7 | 0.5 | · | 0.5 | 0.6 | 0.4 | · | |
| Debt / Equity | 0.6 | 0.6 | 0.7 | · | 0.7 | 0.7 | 0.7 | · | 0.7 | 0.6 | 0.6 | · | 0.6 | 0.6 | 0.6 | · | |
| LT Debt / Equity | 0.6 | 0.6 | 0.7 | · | 0.7 | 0.7 | 0.7 | · | 0.7 | 0.6 | 0.6 | · | 0.6 | 0.6 | 0.6 | · | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | 5.9 | 4.0 | · | 4.6 | 5.3 | 5.7 | · |
Efektywność
| Wskaźnik | Trend | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | |
| Inventory Turnover | 0.7 | 0.7 | 0.7 | · | 0.8 | 0.9 | 0.8 | · | 0.8 | 0.8 | 0.8 | · | 0.8 | 0.7 | 0.7 | · | |
| Receivables Turnover | 1.9 | 1.8 | 2.0 | · | 2.0 | 1.9 | 2.1 | · | 2.0 | 2.0 | 2.1 | · | 2.1 | 2.0 | 2.1 | · |
Na akcję
| Wskaźnik | Trend | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue / Share | $18.11 | $16.80 | $18.37 | · | $19.18 | $18.32 | $17.80 | · | $17.19 | $17.38 | $16.15 | · | $16.94 | $16.88 | $16.07 | · | |
| Cash Flow / Share | · | · | $2.30 | · | · | · | $2.39 | · | · | · | $2.93 | · | · | · | $1.40 | · | |
| Dividend / Share | $1.05 | $1.05 | $1.05 | · | $1.04 | $1.04 | $1.04 | · | $0.95 | $0.95 | $0.95 | · | $0.91 | $0.91 | $0.91 | · | |
| EPS (TTM) | $3.31 | $3.94 | $6.12 | · | $5.48 | $5.16 | $5.94 | · | $4.84 | $4.52 | $4.20 | · | $5.51 | $5.33 | $5.30 | · |
Wycena (TTM)
| Wskaźnik | Trend | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $20.84B | $20.58B | $20.35B | · | $19.81B | $20.07B | $20.64B | · | $19.83B | $19.72B | $19.49B | · | $19.05B | $18.81B | $18.74B | · | |
| Net Income TTM | $941M | $1.14B | $1.76B | · | $1.58B | $1.50B | $1.73B | · | $1.41B | $1.33B | $1.26B | · | $1.66B | $1.62B | $1.61B | · | |
| P/E | 45.7 | 39.9 | 24.9 | · | 24.7 | 34.9 | 30.0 | · | 38.0 | 43.0 | 45.6 | · | 37.7 | 36.5 | 37.7 | · | |
| Earnings Yield | 2.2% | 2.5% | 4.0% | · | 4.0% | 2.9% | 3.3% | · | 2.6% | 2.3% | 2.2% | · | 2.6% | 2.7% | 2.6% | · | |
| Payout Ratio | · | · | 78.3% | · | · | · | 99.7% | · | · | · | 97.9% | · | · | · | 55.2% | · | |
| Annual Payout | $1.17B | $1.19B | $1.19B | · | $1.17B | $1.15B | $1.13B | · | $1.09B | $1.10B | $1.11B | · | $1.12B | $1.10B | $1.09B | · |
Najnowszy okres po lewej · wartości null pokazane jako ·
Sprawozdania finansowe Rachunek zysków i strat, bilans, przepływy pieniężne — roczne, ostatnie 5 lat
| Wskaźnik | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|
| Przychody | $21.84B | $20.18B | $19.37B | $18.87B | $19.13B |
| Marża Operacyjna % | 11.8% | 11.9% | 10.9% | 12.1% | 13.8% |
| Zysk netto | $1.68B | $1.71B | $1.48B | $1.78B | $2.09B |
| Rozwodniony EPS | $5.82 | $5.86 | $4.94 | $5.88 | $6.85 |
| Wskaźnik | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|
| Dług / Kapitał Własny | 0.7 | 0.7 | 0.6 | 0.5 | 0.7 |
| Wskaźnik bieżący | 1.1 | 1.2 | 1.3 | 1.0 | 1.3 |
| Wskaźnik Szybkości | 0.4 | 0.5 | 0.6 | 0.4 | 0.7 |
| Wskaźnik | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|
| Wolny przepływ pieniężny | $2.67B | $3.12B | $2.12B | $1.50B | $3.42B |
Właściciele instytucjonalni (13F) 1 552 emitenci · $46.7B łącznie · Na dzień 30 września 2026
Instytucje, które zgłaszają posiadanie tych akcji w swoich kwartalnych zgłoszeniach SEC Form 13F. Tylko pozycje długie; pojedynczy zgłaszający może pojawić się dwukrotnie dla oddzielnych transz opcji. Duże przeciwstawne pozycje put/call zazwyczaj odzwierciedlają działalność market-makingową lub zabezpieczone zapasy, a nie przekonanie kierunkowe.
| Nowe pozycje | Zamknięte pozycje | Zwiększone | Zmniejszony | Zmiana liczby akcji netto |
|---|---|---|---|---|
| 127 (-30 vs poprzedni kw.) | 141 (-45 vs poprzedni kw.) | 547 (-18 vs poprzedni kw.) | 547 (+12 vs poprzedni kw.) | +9.8M |
Porównano z Q1 2026. Zgłoszenia SEC Form 13F są wymagane w ciągu 45 dni od końca kwartału plus krótki bufor dla spóźnionych zgłoszeń — kwartały mieszczące się jeszcze w tym terminie są pomijane na rzecz ostatniej w pełni zgłoszonej pary.
| Instytucja | Wartość | Akcje | % z śledzonych 13F | Typ |
|---|---|---|---|---|
| VANGUARD GROUP INC | $7 118 281 692 | 36 678 939 | 15,23% | Akcje |
| BlackRock, Inc. | $3 721 532 551 | 24 592 166 | 7,96% | Akcje |
| VANGUARD CAPITAL MANAGEMENT LLC | $2 722 098 919 | 17 987 834 | 5,83% | Akcje |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | $2 483 123 897 | 8 650 967 | 5,31% | Akcje |
| STATE STREET CORP | $2 269 959 685 | 15 000 064 | 4,86% | Akcje |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $2 266 036 001 | 14 974 136 | 4,85% | Akcje |
| First Eagle Investment Management, LLC | $2 090 674 677 | 13 815 335 | 4,47% | Akcje |
| Invesco Ltd. | $1 346 608 236 | 8 898 488 | 2,88% | Akcje |
| GEODE CAPITAL MANAGEMENT, LLC | $1 228 361 034 | 8 141 586 | 2,63% | Akcje |
| FRANKLIN RESOURCES INC | $1 061 064 151 | 7 011 592 | 2,27% | Akcje |
| WELLINGTON MANAGEMENT GROUP LLP | $962 154 023 | 6 357 986 | 2,06% | Akcje |
| GREENHAVEN ASSOCIATES INC | $859 812 872 | 5 681 708 | 1,84% | Akcje |
| NORGES BANK | $630 973 916 | 4 169 523 | 1,35% | Akcje |
| AMERICAN CENTURY COMPANIES INC | $556 370 023 | 3 676 534 | 1,19% | Akcje |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $515 287 516 | 3 398 203 | 1,10% | Akcje |
| MORGAN STANLEY | $502 353 875 | 3 319 590 | 1,08% | Akcje |
| Clearbridge Investments, LLC | $489 222 504 | 3 232 819 | 1,05% | Akcje |
| BANK OF AMERICA CORP /DE/ | $474 992 547 | 3 138 786 | 1,02% | Akcje |
| JPMORGAN CHASE & CO | $440 071 112 | 2 835 692 | 0,94% | Akcje |
| NORTHERN TRUST CORP | $397 274 543 | 2 625 220 | 0,85% | Akcje |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $385 001 377 | 2 544 118 | 0,82% | Akcje |
| HARRIS ASSOCIATES L P | $355 771 231 | 2 350 963 | 0,76% | Akcje |
| DIMENSIONAL FUND ADVISORS LP | $324 096 377 | 2 141 003 | 0,69% | Akcje |
| First Pacific Advisors, LP | $319 426 456 | 2 110 794 | 0,68% | Akcje |
| Legal & General Group Plc | $318 049 508 | 2 101 695 | 0,68% | Akcje |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $296 900 554 | 1 888 320 | 0,64% | Akcje |
| Amundi | $274 921 665 | 1 816 703 | 0,59% | Akcje |
| GOLDMAN SACHS GROUP INC | $266 177 531 | 1 758 921 | 0,57% | Akcje |
| Longview Partners (Guernsey) LTD | $255 761 774 | 1 690 093 | 0,55% | Akcje |
| BRANDES INVESTMENT PARTNERS, LP | $252 955 949 | 1 671 540 | 0,54% | Akcje |
| Bank of New York Mellon Corp | $247 371 528 | 1 634 649 | 0,53% | Akcje |
| VANGUARD FIDUCIARY TRUST CO | $234 270 795 | 1 548 079 | 0,50% | Akcje |
| MACKENZIE FINANCIAL CORP | $216 917 330 | 1 433 406 | 0,46% | Akcje |
| Veritas Asset Management LLP | $210 852 478 | 1 393 329 | 0,45% | Akcje |
| DEUTSCHE BANK AG\ | $204 226 494 | 1 349 544 | 0,44% | Akcje |
| BARCLAYS PLC | $191 750 849 | 1 267 104 | 0,41% | Akcje |
| UBS Group AG | $183 686 019 | 1 213 811 | 0,39% | Akcje |
| WELLS FARGO & COMPANY/MN | $183 226 555 | 1 210 775 | 0,39% | Akcje |
| JARISLOWSKY, FRASER Ltd | $175 028 282 | 935 130 | 0,37% | Akcje |
| COOKE & BIELER LP | $171 990 480 | 1 136 526 | 0,37% | Akcje |
| FORT WASHINGTON INVESTMENT ADVISORS INC /OH/ | $167 650 789 | 1 107 849 | 0,36% | Akcje |
| ProShare Advisors LLC | $162 283 113 | 1 072 379 | 0,35% | Akcje |
| ENVESTNET ASSET MANAGEMENT INC | $156 784 054 | 1 036 041 | 0,34% | Akcje |
| RAYMOND JAMES FINANCIAL INC | $152 018 930 | 1 004 552 | 0,33% | Akcje |
| Focus Partners Wealth | $144 422 511 | 954 318 | 0,31% | Akcje |
| Findlay Park Partners LLP | $143 945 096 | 951 200 | 0,31% | Akcje |
| M&G PLC | $134 044 663 | 887 713 | 0,29% | Akcje |
| FIDUCIARY MANAGEMENT INC /WI/ | $125 873 419 | 831 781 | 0,27% | Akcje |
| Cullen Capital Management, LLC | $124 804 866 | 824 720 | 0,27% | Akcje |
| Swiss National Bank | $121 639 357 | 803 802 | 0,26% | Akcje |
Aktywiści i właściciele 5%+ 5 akcji
Inwestorzy, którzy złożyli SEC Schedule 13D — posiadanie beneficjentów powyżej 5% z zamiarem wpływania na emitenta (udziały aktywistów, kampanie zarządu, M&A). Każdy wiersz pokazuje najnowszy znany stan pozycji tego zgłaszającego.
| Zgłaszający | Złożono | Udział | Status | Cel | Zgłoszenie |
|---|---|---|---|---|---|
| Niezgłoszona osoba raportująca | 8 września 2006 | · | Pierwotne zgłoszenie | · | SEC |
| Niezgłoszona osoba raportująca | 1 września 2006 | · | Pierwotne zgłoszenie | · | SEC |
| Niezgłoszona osoba raportująca | 25 sierpnia 2006 | · | Pierwotne zgłoszenie | · | SEC |
| Niezgłoszona osoba raportująca | 16 sierpnia 2006 | · | Pierwotne zgłoszenie | · | SEC |
| Niezgłoszona osoba raportująca | 14 sierpnia 2006 | · | Pierwotne zgłoszenie | Inwestycja pasywna | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Insiderzy spółki 83 insiderów · 47 dyrektorzy generalni · 27 dyrektorzy
| Insider | Rola | Ostatnia aktywność | Posiadane akcje | Kupna 12m | Sprzedaże 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Thomas E Polen Jr | Chairman, CEO and President | 13 sierpnia 2026 M | 110 163 | 0 | 2 | $-1 172 631 |
| Vitor Roque | EVP & Chief Financial Officer | 2 września 2026 F | 8 041 | 0 | 0 | $0 |
| Christopher Delorefice | EVP & Chief Financial Officer | 26 listopada 2025 F | 22 982 | 0 | 0 | $0 |
| Christopher R Reidy | CFO and EVP of Administration | 26 listopada 2021 A | 31 524 | 0 | 0 | $0 |
| David V Elkins | Executive VP and CFO | 9 listopada 2012 D | 0 | 0 | 0 | $0 |
| Michael Feld | EVP, Chief Revenue Officer | 28 września 2026 S | 19 644 | 0 | 12 | $-170 822 |
| Roland Goette | EVP and President, EMEA | 11 sierpnia 2026 S | 14 856 | 0 | 1 | $-440 888 |
| Bilal Muhsin | EVP & President Connected Care | 2 lipca 2026 F | 41 359 | 0 | 0 | $0 |
| Michael David Garrison | EVP & Pres Med.Essntl&BioPharm | 24 czerwca 2026 S | 13 172 | 0 | 5 | $-784 162 |
| Peter Menziuso | EVP and President, BDI | 1 czerwca 2026 A | 14 258 | 0 | 0 | $0 |
| Shana Carol Neal | EVP and Chief People Officer | 6 kwietnia 2026 F | 23 966 | 0 | 0 | $0 |
| Lanesha Minnix | EVP and General Counsel | 16 marca 2026 A | 7 492 | 0 | 0 | $0 |
| Pamela L. Spikner | SVP Controller & CAO | 2 marca 2026 A | 3 323 | 0 | 0 | $0 |
| David Shan | EVP and Chief ISC Officer | 3 stycznia 2026 F | 8 926 | 0 | 0 | $0 |
| Richard Byrd | EVP & President Interventional | 26 listopada 2025 F | 13 849 | 0 | 0 | $0 |
| Pavan Kumar Mocherla | EVP & President, Greater Asia | 26 listopada 2025 A | 5 763 | 0 | 0 | $0 |
| Michelle Quinn | EVP and General Counsel | 26 listopada 2024 A | 6 927 | 0 | 0 | $0 |
| Antoine C Ezell | EVP, President Americas & CMO | 26 listopada 2024 A | 11 970 | 0 | 0 | $0 |
| Thomas J Spoerel | SVPController & Chief Acct Off | 1 lipca 2024 F | 1 928 | 0 | 0 | $0 |
| David Hickey | EVP & President, Life Sciences | 26 listopada 2023 A | 5 862 | 0 | 0 | $0 |
| Samrat S. Khichi | EVP and General Counsel | 21 grudnia 2022 G | 9 251 | 0 | 0 | $0 |
| Rishi Grover | EVP and Chief ISC Officer | 8 lipca 2022 A | 9 439 | 0 | 0 | $0 |
| James Lim | Executive Vice President | 17 czerwca 2022 A | 23 941 | 0 | 0 | $0 |
| Betty D Larson | EVP HR & CHRO | 25 lutego 2022 M | 5 872 | 0 | 0 | $0 |
| Simon D Campion | EVP and Segment President | 11 lutego 2022 G | 10 319 | 0 | 0 | $0 |
| Alexandre Conroy | EVP of Integrated Supply Chain | 3 lutego 2022 M | 21 260 | 0 | 0 | $0 |
| Ribo Alberto Mas | EVP and Pres, Life Sciences | 26 listopada 2021 A | 11 662 | 0 | 0 | $0 |
| Vincent A Forlenza | Chairman of the Board | 15 grudnia 2020 G | 194 048 | 0 | 0 | $0 |
| Patrick Kaltenbach | EVP & Pres Life Sciences | 26 listopada 2020 A | 10 340 | 0 | 0 | $0 |
| Charles R Bodner | SVP Corp Fin Chief Acct Office | 6 września 2019 M | 2 037 | 0 | 0 | $0 |
| James W Borzi | EVP & Chief Supply Chain Offcr | 30 listopada 2018 M | 2 775 | 0 | 0 | $0 |
| William A Tozzi | EVP Pres Interventional | 2 lipca 2018 A | 12 830 | 0 | 0 | $0 |
| Nabil Shabshab | Executive Vice President | 11 maja 2018 M | 7 811 | 0 | 0 | $0 |
| John E Gallagher | VP, Corp Finance and Treasurer | 2 marca 2018 F | 1 975 | 0 | 0 | $0 |
| Linda M Tharby | Executive Vice President | 1 lutego 2018 M | 13 437 | 0 | 0 | $0 |
| John P Groetelaars | EVP | 2 stycznia 2018 A | 42 508 | 0 | 0 | $0 |
| Ellen R Strahlman | Senior Vice President | 25 listopada 2017 F | 6 898 | 0 | 0 | $0 |
| Gary M Cohen | Executive Vice President | 11 września 2017 M | 71 770 | 0 | 0 | $0 |
| Stephen Sichak | Executive Vice President | 8 września 2017 M | 7 953 | 0 | 0 | $0 |
| Jeffrey S Sherman | Sr. VP and General Counsel | 25 maja 2017 M | 22 094 | 0 | 0 | $0 |
| Jerome V Hurwitz | Executive Vice President | 6 maja 2016 S | 3 027 | 0 | 0 | $0 |
| William A Kozy | Executive Vice President | 9 grudnia 2015 S | 68 823 | 0 | 0 | $0 |
| Joseph Mercurio | VP and Corporate Controller | 25 listopada 2014 A | 1 932 | 0 | 0 | $0 |
| Donna M Boles | Senior VP - Human Resources | 17 maja 2013 M | 14 607 | 0 | 0 | $0 |
| Suketu Upadhyay | Senior VP and Controller | 20 listopada 2012 A | 3 525 | 0 | 0 | $0 |
| William E. Rhodes | Senior Vice President | 20 listopada 2012 A | 5 972 | 0 | 0 | $0 |
| Edward J Ludwig | Chairman | 20 marca 2012 G | 95 188 | 0 | 0 | $0 |
| Carrie L Byington | Dyrektor | 6 sierpnia 2026 A | 5 018 | 0 | 0 | $0 |
| Robert Luther Huffines | Dyrektor | 6 sierpnia 2026 A | 1 279 | 0 | 0 | $0 |
| Bertram L Scott | Dyrektor | 18 lutego 2026 S | 36 763 | 0 | 2 | $-212 345 |
| Christopher Ian Montague Jones | Dyrektor | 4 lutego 2026 A | 24 304 | 0 | 0 | $0 |
| Joanne Waldstreicher | Dyrektor | 27 stycznia 2026 A | 3 391 | 0 | 0 | $0 |
| Jacqueline Wright | Dyrektor | 27 stycznia 2026 A | 1 279 | 0 | 0 | $0 |
| William M Brown | Dyrektor | 27 stycznia 2026 A | 4 663 | 0 | 0 | $0 |
| Jeffrey William Henderson | Dyrektor | 27 stycznia 2026 A | 9 143 | 0 | 0 | $0 |
| Gregory Hayes | Dyrektor | 27 stycznia 2026 A | 7 159 | 0 | 0 | $0 |
| Andrew R Eckert | Dyrektor | 27 stycznia 2026 A | 10 423 | 0 | 0 | $0 |
| Timothy M Ring | Dyrektor | 27 stycznia 2026 A | 59 160 | 0 | 0 | $0 |
| Catherine M Burzik | Dyrektor | 28 stycznia 2025 A | 14 264 | 0 | 0 | $0 |
| LARSEN MARSHALL O | Dyrektor | 24 stycznia 2023 A | 28 919 | 0 | 0 | $0 |
| Claire Pomeroy | Dyrektor | 25 stycznia 2022 A | 9 982 | 0 | 0 | $0 |
| David F Melcher | Dyrektor | 25 stycznia 2022 A | 6 180 | 0 | 0 | $0 |
| Rebecca W Rimel | Dyrektor | 8 września 2021 S | 10 618 | 0 | 0 | $0 |
| Gary A Mecklenburg | Dyrektor | 6 listopada 2018 A | 25 453 | 0 | 0 | $0 |
| Wilard J Overlock JR | Dyrektor | 6 listopada 2018 A | 19 442 | 0 | 0 | $0 |
| James F Orr | Dyrektor | 24 stycznia 2017 A | 24 257 | 0 | 0 | $0 |
| Basil Anderson | Dyrektor | 26 stycznia 2016 A | 22 596 | 0 | 0 | $0 |
| Henry P Becton JR | Dyrektor | 3 listopada 2015 A | 112 683 | 0 | 0 | $0 |
| Edward Degraan | Dyrektor | 27 stycznia 2015 A | 22 416 | 0 | 0 | $0 |
| Alfred Sommer | Dyrektor | 28 stycznia 2014 A | 20 689 | 0 | 0 | $0 |
| Adel Mahmoud | Dyrektor | 29 stycznia 2013 A | 13 746 | 0 | 0 | $0 |
| Claire Fraser | · | 10 września 2025 S | 22 226 | 0 | 0 | $0 |
| David T Durack | · | 28 kwietnia 2011 M | 8 908 | 0 | 0 | $0 |
| Cathy E. Minehan | · | 1 lutego 2011 A | 8 535 | 0 | 0 | $0 |
| Scott P Bruder | · | 23 listopada 2010 A | 7 626 | 0 | 0 | $0 |
| Patricia B Shrader | · | 23 listopada 2010 A | 11 250 | 0 | 0 | $0 |
| John R Considine | · | 24 listopada 2009 A | 93 438 | 0 | 0 | $0 |
| Alfred John Hanson | · | 25 listopada 2008 A | 46 146 | 0 | 0 | $0 |
| James E Perrella | · | 31 października 2007 A | 18 520 | 0 | 0 | $0 |
| Margeretha Af Ugglas | · | 31 stycznia 2007 A | 15 920 | 0 | 0 | $0 |
| Jean Marc Dageville | · | 8 grudnia 2004 M | 4 658 | 0 | 0 | $0 |
| Harry N Beaty | · | 3 maja 2004 M | 9 204 | 0 | 0 | $0 |
| OLSON FRANK ALBERT | · | 11 lutego 2004 A | 21 200 | 0 | 0 | $0 |
Insiderzy z zgłoszeń SEC Form 3/4/5; netto = tylko otwarty rynek P/S
Posiadanie ETF-ów Posiadane przez 145 funduszy ETF
Waga odzwierciedla wyłącznie bezpośrednie udziały kapitałowe (N-PORT); fundusze oparte na dźwigni lub instrumentach pochodnych mogą posiadać dodatkowe ekspozycje na swapy, które nie są pokazane.
| Fundusz | Waga | Jednostki | Na dzień | Źródło |
|---|---|---|---|---|
| IHI · iShares Trust | 5,24% | 943 719 SH | 11 września 2026 | Dziennie |
| CZA · Invesco Exchange-Traded Fund Trust | 2,46% | 27 873 SH | 2 października 2026 | Dziennie |
| EQTY · Valued Advisers Trust | 2,14% | 184 537 NS | 31 lipca 2026 | N-PORT |
| UPGD · Invesco Exchange-Traded Fund Trust | 1,98% | 12 776 SH | 2 października 2026 | Dziennie |
| RSPH · Invesco Exchange-Traded Fund Trust | 1,64% | 80 100 SH | 2 października 2026 | Dziennie |
| EPOL · iShares Trust | 1,60% | 69 343 SH | 11 września 2026 | Dziennie |
| FXH · First Trust Exchange-Traded AlphaDE… | 1,49% | 94 088 NS | 31 lipca 2026 | N-PORT |
| KNG · First Trust Exchange-Traded Fund IV | 1,49% | 317 073 NS | 31 lipca 2026 | N-PORT |
| COWZ · Pacer Funds Trust | 1,01% | 1 134 820 NS | 31 lipca 2026 | N-PORT |
| IYH · iShares Trust | 0,81% | 166 236 SH | 11 września 2026 | Dziennie |
| RGEF · Tidal Trust III | 0,73% | 35 725 NS | 31 lipca 2026 | N-PORT |
| VOE · VANGUARD INDEX FUNDS | 0,72% | 1 769 988 SH | 19 sierpnia 2026 | Dziennie |
| FHLC · FIDELITY COVINGTON TRUST | 0,68% | 135 578 NS | 31 lipca 2026 | N-PORT |
| IMCV · iShares Trust | 0,68% | 44 851 SH | 11 września 2026 | Dziennie |
| REVS · Columbia ETF Trust I | 0,65% | 13 100 NS | 31 lipca 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0,64% | 856 811 SH | 19 sierpnia 2026 | Dziennie |
| QUVU · Hartford Funds Exchange-Traded Trust | 0,62% | 6 797 NS | 31 lipca 2026 | N-PORT |
| IXJ · iShares Trust | 0,62% | 144 713 SH | 11 września 2026 | Dziennie |
| CURE · Direxion Shares ETF Trust | 0,52% | 5 422 NS | 31 lipca 2026 | N-PORT |
| IWS · iShares Trust | 0,49% | 424 696 SH | 11 września 2026 | Dziennie |
| EQIN · Columbia ETF Trust I | 0,48% | 8 836 NS | 31 lipca 2026 | N-PORT |
| RECS · Columbia ETF Trust I | 0,42% | 148 656 NS | 31 lipca 2026 | N-PORT |
| FDLO · FIDELITY COVINGTON TRUST | 0,41% | 35 456 NS | 31 lipca 2026 | N-PORT |
| DIVB · iShares Trust | 0,40% | 46 677 SH | 11 września 2026 | Dziennie |
| VO · VANGUARD INDEX FUNDS | 0,40% | 5 971 067 SH | 19 sierpnia 2026 | Dziennie |
| BSCR · Invesco Exchange-Traded Self-Indexe… | 0,40% | 18 133 000 | 2 października 2026 | Dziennie |
| HUSV · First Trust Exchange-Traded Fund III | 0,38% | 1 706 NS | 31 lipca 2026 | N-PORT |
| FTA · First Trust Exchange-Traded AlphaDE… | 0,38% | 31 777 NS | 31 lipca 2026 | N-PORT |
| VFMV · VANGUARD WELLINGTON FUND | 0,37% | 10 309 SH | 19 sierpnia 2026 | Dziennie |
| IWR · iShares Trust | 0,37% | 1 164 966 SH | 11 września 2026 | Dziennie |
| VLUE · iShares Trust | 0,36% | 194 404 SH | 11 września 2026 | Dziennie |
| JPME · J.P. Morgan Exchange-Traded Fund Tr… | 0,35% | 9 750 NS | 31 lipca 2026 | N-PORT |
| IMCB · iShares Trust | 0,34% | 32 267 SH | 11 września 2026 | Dziennie |
| JPUS · J.P. Morgan Exchange-Traded Fund Tr… | 0,34% | 9 256 NS | 31 lipca 2026 | N-PORT |
| VFVA · VANGUARD WELLINGTON FUND | 0,33% | 18 654 SH | 19 sierpnia 2026 | Dziennie |
| FEX · First Trust Exchange-Traded AlphaDE… | 0,30% | 27 935 NS | 31 lipca 2026 | N-PORT |
| DGRO · iShares Trust | 0,29% | 717 789 SH | 11 września 2026 | Dziennie |
| XOEF · iShares Trust | 0,27% | 347 SH | 11 września 2026 | Dziennie |
| DFLV · Dimensional ETF Trust | 0,26% | 104 844 NS | 31 lipca 2026 | N-PORT |
| SIZE · iShares Trust | 0,23% | 5 494 SH | 11 września 2026 | Dziennie |
| RSP · Invesco Exchange-Traded Fund Trust | 0,20% | 1 085 457 SH | 2 października 2026 | Dziennie |
| IUS · Invesco Exchange-Traded Self-Indexe… | 0,20% | 10 851 SH | 2 października 2026 | Dziennie |
| EUSA · iShares, Inc. | 0,19% | 20 800 SH | 11 września 2026 | Dziennie |
| FAB · First Trust Exchange-Traded AlphaDE… | 0,19% | 1 919 NS | 31 lipca 2026 | N-PORT |
| BSCU · Invesco Exchange-Traded Self-Indexe… | 0,19% | 5 597 000 | 2 października 2026 | Dziennie |
| DFUV · Dimensional ETF Trust | 0,18% | 171 825 NS | 31 lipca 2026 | N-PORT |
| BSCS · Invesco Exchange-Traded Self-Indexe… | 0,18% | 6 482 000 | 2 października 2026 | Dziennie |
| PFIG · Invesco Exchange-Traded Fund Trust … | 0,18% | 255 000 | 1 października 2026 | Dziennie |
| VIG · VANGUARD SPECIALIZED FUNDS | 0,18% | 1 556 657 SH | 19 sierpnia 2026 | Dziennie |
| VYM · VANGUARD WHITEHALL FUNDS | 0,18% | 1 134 690 SH | 19 sierpnia 2026 | Dziennie |
| PFM · Invesco Exchange-Traded Fund Trust | 0,18% | 7 746 SH | 2 października 2026 | Dziennie |
| FEUS · FlexShares Trust | 0,17% | 1 155 NS | 31 lipca 2026 | N-PORT |
| IVE · iShares Trust | 0,16% | 457 195 SH | 11 września 2026 | Dziennie |
| VTV · VANGUARD INDEX FUNDS | 0,16% | 2 617 912 SH | 19 sierpnia 2026 | Dziennie |
| IUSV · iShares Trust | 0,15% | 240 462 SH | 11 września 2026 | Dziennie |
| BSCT · Invesco Exchange-Traded Self-Indexe… | 0,15% | 4 447 000 | 2 października 2026 | Dziennie |
| ILCV · iShares Trust | 0,14% | 10 712 SH | 11 września 2026 | Dziennie |
| VOOV · VANGUARD ADMIRAL FUNDS | 0,14% | 63 464 SH | 19 sierpnia 2026 | Dziennie |
| EMGF · iShares, Inc. | 0,14% | 14 306 SH | 10 września 2026 | Dziennie |
| DSI · iShares Trust | 0,14% | 42 114 SH | 11 września 2026 | Dziennie |
| IWD · iShares Trust | 0,14% | 632 304 SH | 11 września 2026 | Dziennie |
| PRF · Invesco Exchange-Traded Fund Trust | 0,12% | 68 767 SH | 2 października 2026 | Dziennie |
| VONV · VANGUARD SCOTTSDALE FUNDS | 0,12% | 171 632 SH | 19 sierpnia 2026 | Dziennie |
| GLBL · Pacer Funds Trust | 0,12% | 8 NS | 31 lipca 2026 | N-PORT |
| DFVX · Dimensional ETF Trust | 0,12% | 3 749 NS | 31 lipca 2026 | N-PORT |
| RWL · Invesco Exchange-Traded Fund Trust … | 0,11% | 57 721 SH | 2 października 2026 | Dziennie |
| ESG · FlexShares Trust | 0,11% | 840 NS | 31 lipca 2026 | N-PORT |
| QVML · Invesco Exchange-Traded Fund Trust … | 0,10% | 9 358 SH | 2 października 2026 | Dziennie |
| HDUS · Lattice Strategies Trust | 0,10% | 1 192 NS | 31 lipca 2026 | N-PORT |
| EQAL · Invesco Exchange-Traded Fund Trust … | 0,10% | 4 285 SH | 2 października 2026 | Dziennie |
| TOPC · iShares Trust | 0,09% | 171 SH | 11 września 2026 | Dziennie |
| ACVF · ETF Opportunities Trust | 0,09% | 795 NS | 31 lipca 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,08% | 244 485 NS | 31 lipca 2026 | N-PORT |
| XVV · iShares Trust | 0,08% | 3 163 SH | 11 września 2026 | Dziennie |
| PBP · Invesco Exchange-Traded Fund Trust | 0,07% | 1 621 SH | 2 października 2026 | Dziennie |
| PBUS · Invesco Exchange-Traded Fund Trust … | 0,07% | 47 745 SH | 2 października 2026 | Dziennie |
| IVV · iShares Trust | 0,07% | 3 473 127 SH | 11 września 2026 | Dziennie |
| CRBN · iShares Trust | 0,07% | 4 897 SH | 11 września 2026 | Dziennie |
| ILCB · iShares Trust | 0,07% | 5 340 SH | 11 września 2026 | Dziennie |
| BKLC · BNY Mellon ETF Trust | 0,07% | 24 016 NS | 31 lipca 2026 | N-PORT |
| IWB · iShares Trust | 0,07% | 197 581 SH | 11 września 2026 | Dziennie |
| BBUS · J.P. Morgan Exchange-Traded Fund Tr… | 0,07% | 38 024 NS | 31 lipca 2026 | N-PORT |
| PTLC · Pacer Funds Trust | 0,07% | 13 955 NS | 31 lipca 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0,07% | 53 117 NS | 31 lipca 2026 | N-PORT |
| VOTE · TCW ETF Trust | 0,07% | 4 662 NS | 31 lipca 2026 | N-PORT |
| VV · VANGUARD INDEX FUNDS | 0,07% | 321 801 SH | 19 sierpnia 2026 | Dziennie |
| ESGV · VANGUARD WORLD FUND | 0,07% | 64 270 SH | 19 sierpnia 2026 | Dziennie |
| TOV · EA Series Trust | 0,07% | 1 117 NS | 31 lipca 2026 | N-PORT |
| IYY · iShares Trust | 0,07% | 11 794 SH | 11 września 2026 | Dziennie |
| DXUV · Dimensional ETF Trust | 0,07% | 2 283 NS | 31 lipca 2026 | N-PORT |
| VOXP · Advisors Series Trust | 0,07% | 24 NS | 31 lipca 2026 | N-PORT |
| IWV · iShares Trust | 0,07% | 78 106 SH | 11 września 2026 | Dziennie |
| USCL · iShares Trust | 0,07% | 10 939 SH | 11 września 2026 | Dziennie |
| ITOT · iShares Trust | 0,07% | 359 241 SH | 11 września 2026 | Dziennie |
| DFUS · Dimensional ETF Trust | 0,07% | 83 341 NS | 31 lipca 2026 | N-PORT |
| SPUU · Direxion Shares ETF Trust | 0,07% | 1 039 NS | 31 lipca 2026 | N-PORT |
| QDPL · Pacer Funds Trust | 0,06% | 6 630 NS | 31 lipca 2026 | N-PORT |
| LRGF · iShares Trust | 0,06% | 13 430 SH | 11 września 2026 | Dziennie |
| PHDG · Invesco Actively Managed Exchange-T… | 0,06% | 215 SH | 2 października 2026 | Dziennie |
| VOO · VANGUARD INDEX FUNDS | 0,06% | 7 153 108 SH | 19 sierpnia 2026 | Dziennie |
| VTI · VANGUARD INDEX FUNDS | 0,06% | 8 748 767 SH | 19 sierpnia 2026 | Dziennie |
| VSS · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,06% | 47 858 SH | 19 sierpnia 2026 | Dziennie |
| VONE · VANGUARD SCOTTSDALE FUNDS | 0,06% | 47 190 SH | 19 sierpnia 2026 | Dziennie |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,06% | 23 933 SH | 19 sierpnia 2026 | Dziennie |
| TOK · iShares Trust | 0,06% | 795 SH | 11 września 2026 | Dziennie |
| DCOR · Dimensional ETF Trust | 0,06% | 11 787 NS | 31 lipca 2026 | N-PORT |
| HCMT · Direxion Shares ETF Trust | 0,06% | 1 923 NS | 31 lipca 2026 | N-PORT |
| URTH · iShares, Inc. | 0,06% | 25 569 SH | 11 września 2026 | Dziennie |
| JFLI · J.P. Morgan Exchange-Traded Fund Tr… | 0,05% | 156 NS | 31 lipca 2026 | N-PORT |
| SPXL · Direxion Shares ETF Trust | 0,05% | 21 539 NS | 31 lipca 2026 | N-PORT |
| TILT · FlexShares Trust | 0,05% | 6 952 NS | 31 lipca 2026 | N-PORT |
| LDEM · iShares Trust | 0,05% | 91 SH | 11 września 2026 | Dziennie |
| ACWI · iShares Trust | 0,05% | 94 438 SH | 11 września 2026 | Dziennie |
| DFSU · Dimensional ETF Trust | 0,05% | 6 917 NS | 31 lipca 2026 | N-PORT |
| EMXF · iShares Trust | 0,04% | 384 SH | 11 września 2026 | Dziennie |
| OMFL · Invesco Exchange-Traded Self-Indexe… | 0,04% | 11 545 SH | 2 października 2026 | Dziennie |
| ROUS · Lattice Strategies Trust | 0,04% | 1 753 NS | 31 lipca 2026 | N-PORT |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,04% | 247 589 SH | 19 sierpnia 2026 | Dziennie |
| PDN · Invesco Exchange-Traded Fund Trust … | 0,04% | 796 SH | 2 października 2026 | Dziennie |
| GLOF · iShares Trust | 0,04% | 380 SH | 11 września 2026 | Dziennie |
| JVAL · J.P. Morgan Exchange-Traded Fund Tr… | 0,04% | 1 792 NS | 31 lipca 2026 | N-PORT |
| EMXC · iShares, Inc. | 0,02% | 33 336 SH | 11 września 2026 | Dziennie |
| VGK · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,02% | 30 768 SH | 19 sierpnia 2026 | Dziennie |
| EEM · iShares, Inc. | 0,02% | 31 606 SH | 10 września 2026 | Dziennie |
| IEMG · iShares, Inc. | 0,02% | 152 904 SH | 10 września 2026 | Dziennie |
| LGDX · Tidal Trust III | 0,01% | 113 NS | 31 lipca 2026 | N-PORT |
| VXUS · VANGUARD STAR FUNDS | 0,01% | 186 147 SH | 19 sierpnia 2026 | Dziennie |
| VEA · VANGUARD TAX-MANAGED FUNDS | 0,01% | 125 091 SH | 19 sierpnia 2026 | Dziennie |
| VSGX · VANGUARD WORLD FUND | 0,01% | 2 529 SH | 19 sierpnia 2026 | Dziennie |
| AQLT · iShares Trust | 0,01% | 158 SH | 10 września 2026 | Dziennie |
| PEVC · Pacer Funds Trust | 0,01% | 1 NS | 31 lipca 2026 | N-PORT |
| ACWX · iShares Trust | 0,01% | 3 911 SH | 10 września 2026 | Dziennie |
| IXUS · iShares Trust | 0,01% | 18 527 SH | 11 września 2026 | Dziennie |
| BIV · VANGUARD BOND INDEX FUNDS | · | · | 15 lipca 2026 | Dziennie |
| BSV · VANGUARD BOND INDEX FUNDS | · | · | 15 lipca 2026 | Dziennie |
| BND · VANGUARD BOND INDEX FUNDS | · | · | 15 lipca 2026 | Dziennie |
| VUSB · VANGUARD BOND INDEX FUNDS | · | · | 15 lipca 2026 | Dziennie |
| VSDB · VANGUARD MALVERN FUNDS | · | · | 15 lipca 2026 | Dziennie |
| VCSH · VANGUARD SCOTTSDALE FUNDS | · | · | 15 lipca 2026 | Dziennie |
| VCIT · VANGUARD SCOTTSDALE FUNDS | · | · | 15 lipca 2026 | Dziennie |
| VCLT · VANGUARD SCOTTSDALE FUNDS | · | · | 15 lipca 2026 | Dziennie |
| VTC · VANGUARD SCOTTSDALE FUNDS | · | · | 30 lipca 2026 | Dziennie |
| BNDW · VANGUARD SCOTTSDALE FUNDS | · | · | 30 lipca 2026 | Dziennie |
| BNDX · VANGUARD CHARLOTTE FUNDS | · | · | 15 lipca 2026 | Dziennie |
| VCEB · VANGUARD WORLD FUND | · | · | 30 lipca 2026 | Dziennie |
BDX Konsensus analityków Bycze i niedźwiedzie opinie analityków, 12-miesięczny cel cenowy, potencjał wzrostu
12-miesięczny cel cenowy
12 analityków · 2026-10-01Średnia cel $195.67 +10,7%
Porównanie z porównywalnymi firmami (podbranża GICS) Kluczowe metryki w porównaniu do konkurentów z sektora
Podstawa R/R, ceny według zamknięcia z ostatniego końca roku obrotowego każdej spółki.
| Ticker | Kapitalizacja Rynkowa | P/E | Przychody r/r | Marża Netto | ROE | Marża brutto |
|---|---|---|---|---|---|---|
| BDX | · | 25.3 | 8.2% | 7.7% | 6.5% | · |
| ABT | $250.18B | 33.7 | 5.7% | 14.7% | 13.1% | · |
| ISRG | $201.11B | 72.0 | 20.5% | 28.4% | 16.7% | 66.0% |
| SYK | $134.44B | 41.8 | 11.2% | 12.9% | 15.1% | 64.0% |
| BSX | · | 49.1 | 19.9% | 14.4% | 12.6% | 69.0% |
| EW | $49.50B | 46.6 | 11.6% | 17.7% | 10.6% | 78.0% |
| IDXX | $53.93B | 51.7 | 10.4% | 24.6% | 69.2% | 61.8% |
| DXCM | $25.54B | 31.8 | 15.6% | 17.9% | 31.4% | 60.1% |
| RMD | $28.11B | 18.7 | 9.8% | 26.9% | 23.6% | 61.1% |
| GEHC | · | 18.0 | 4.8% | 10.1% | 22.1% | 40.0% |
| ZBH | $28.66B | 25.3 | 7.2% | 8.6% | 5.6% | · |
Najnowsze wiadomości Najnowsze nagłówki wspominające o tej firmie
Moje wskaźniki Twoja osobista lista obserwowanych — wybrane wiersze z Pełnych Fundamentów
Wybierz wskaźniki, które są dla Ciebie ważne — kliknij + obok dowolnego wiersza w sekcji Pełne dane fundamentalne powyżej.
Twój wybór został zapisany i będzie Ci towarzyszył we wszystkich tickerach.